‘LysaKare’, the drug concomitantly used with the neuroendocrine tumor treatment ‘Latathera’ may soon be prescribed at general hospitals.

According to industry sources, Novartis Korea’s ‘LysaKare (L-arginine hcl/L-lysine hcl) has passed the drug committee (DC) reviews at 3 of the Big 5 general hospitals – Samsung Medical Center, Seoul National University Hospital, Seoul Asan Medical Center - in Korea.

LysaKare was approved as a drug to be used concomitantly with Novartis’s orphan drug Lutathera (lutetium), a neuroendocrine tumor treatment that was approved in July 2020.

Lutathera is a radioactive targeted therapy that increases the dose of radiation in the tumo